CRBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Corbus Pharmaceuticals Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.46−0.06 (-1.33%)
Close on Oct 19, 2026
- Market cap
- $86.56M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -223.4% | -432.7% | -54.2% | |
| Return on assets | -130.0% | -147.0% | -48.5% | |
| Current ratio | 1.96 | 2.89 | 8.07 | |
| Debt to equity | – | 0.40 | – | |
| Net debt to EBITDA | – | 0.55× | – | |
| Interest coverage | -6415.7× | -109.0× | – | |
| Capex to revenue | 18.5% | 12.3% | – | |
| Diluted shares | 1M | 3M | 13M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Corbus Pharmaceuticals generated $228.11M from operations and spent $74.62K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$228.11M
Used
$74.62K
Capital expenditure$74.62K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-5176.4%
×Asset turnover0.01×
×Equity multiplier1.84×
=Return on equity, FY2021-79.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2021 | -5176.4% | 0.01× | 1.84× | -79.8% |
| FY2020 | -2826.1% | 0.05× | 2.94× | -432.7% |
| FY2019 | -197.7% | 0.75× | 2.85× | -424.3% |
| FY2018 | -1154.5% | 0.08× | 1.34× | -130.5% |
| FY2017 | -1328.6% | 0.06× | 1.27× | -97.2% |
| FY2016 | -1046.3% | 0.12× | 1.72× | -223.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$78.54M
- Cash generatingOperating cash flow above zero-$64.49M
- Return on assets improvedROA up on the prior year-142.2% → -50.4%
- Earnings backed by cashOperating cash flow above net income-$64.49M vs -$78.54M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose12.94 → 8.07
- No dilutionShare count did not rise11M → 13M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –